The Company . is a biopharmaceutical company engaged in developing clinical-stage advanced cell therapies. The Company is developing advanced cell therapies to target various orthopedic diseases and degenerative disorders. Its platform technology consists of a combination of allogeneic primary cells combined with genetically modified cells in one injectable therapeutic dose. TG-C, its lead product candidate, is developed for treating osteoarthritis (OA) of the knee. TG-C is an allogeneic (donor) cell and gene therapy involving primary human chondrocytes (cartilage cells) and human cells transduced to express the therapeutic growth factor TGF-ss1, which is delivered via one intra-articular injection into the knee. Its product pipelines fall under the category, such as osteoarthritis, musculoskeletal system disorder, and vet medicine. It is also developing therapies for musculoskeletal system disorders, such as rheumatoid arthritis, meniscus, and spinal discs. The Company was established on June 9, 1999. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on November 6, 2017.
Headquarters
Md, Usa 9713 Key West Ave Suite 300
Rockville; Maryland;
Contact Details: Purchase the Kolon TissueGene, Inc report to view the information.
Website: http://tissuegene.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service